Review of targeted treatments in fragile X syndrome

Andrew Ligsay, Randi J Hagerman

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the leading single-gene cause of autism spectrum disorders. It is due to a loss of the fragile X mental retardation protein, which leads to molecular, behavioral, and cognitive deficits in these patients. Improvements in our understanding of its pathophysiology have led to the development of numerous targeted treatments in FXS as highlighted by metabotropic glutamate receptor antagonists and gamma-Aminobutyric acid receptor modulators. This review will summarize relevant pre-clinical data and results from clinical trials in human subjects with FXS. It will also highlight upcoming studies and future directions for clinical trials as well.

Original languageEnglish (US)
Pages (from-to)158-167
Number of pages10
JournalIntractable and Rare Diseases Research
Issue number3
StatePublished - 2016


  • Clinical trials
  • Fragile X syndrome
  • Targeted treatments

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Review of targeted treatments in fragile X syndrome'. Together they form a unique fingerprint.

Cite this